ORGANOTHERAPEUTICS
OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.
ORGANOTHERAPEUTICS
Industry:
Biopharma Biotechnology Life Science Pharmaceutical
Founded:
2019-01-01
Address:
Esch-sur-alzette, Luxembourg, Luxembourg
Country:
Luxembourg
Website Url:
http://www.organo-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+4917680774615
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Google Maps Contact Form 7 Person Schema Gravatar Profiles
Similar Organizations
Okairos
Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
Current Employees Featured
Founder
Investors List
Creative Destruction Lab (CDL)
Creative Destruction Lab (CDL) investment in Non Equity Assistance - OrganoTherapeutics
MassChallenge
MassChallenge investment in Non Equity Assistance - OrganoTherapeutics
Official Site Inspections
http://www.organo-therapeutics.com Semrush global rank: 5.24 M Semrush visits lastest month: 1.56 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "OrganoTherapeutics"
About - OrganoTherapeutics
OrganoTherapeutics is a spin-off project from the University of Luxembourg. We use innovative human mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease.See details»
OrganoTherapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +4917680774615 OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and …See details»
Organo Therapeutics 2025 Company Profile: Valuation, Funding ...
Organo Therapeutics General Information Description. Developer of medical drugs intended to target Parkinson's disease. The company uses three-dimensional (3D) models derived from a …See details»
OrganoTherapeutics - LinkedIn
OrganoTherapeutics | 1,598 followers on LinkedIn. Using Midbrain Organoids for the development of new Therapeutics against Parkinson`s Disease. | OrganoTherapeutics uses cutting-edge …See details»
OrganoTherapeutics SARL-S | Luxembourg Startup - Gust
Website organo-therapeutics.com; Company Summary Pillars of OT: 1) Our proprietary model, the brain organoids, which recapitulate the brain area affected by Parkinson’s disease (PD). 2) …See details»
OrganoTherapeutics SARL - Esch-sur-Alzette, Luxembourg
May 4, 2021 organo-therapeutics.com. Profile News. About OrganoTherapeutics. OrganoTherapeutics is a spin-off project from the University of Luxembourg. …See details»
Overview, News & Similar companies - ZoomInfo.com
Mar 29, 2022 Who is OrganoTherapeutics. OrganoTherapeutics is a recent spin-off company from the University of Luxembourg, which uses cutting-edge human-specific mini-brains for the …See details»
OrganoTherapeutics - Funding, Financials, Valuation & Investors
Jul 26, 2023 OrganoTherapeutics use mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease.See details»
OrganoTherapeutics | BIO-Europe
OrganoTherapeutics S.a.r.l. (OT) makes use of a proprietary human-specific 3D in vitro model, the so-called midbrain organoids, for the discovery and development of effective drug …See details»
OrganoTherapeutics - YouTube
OrganoTherapeutics has the mission to accelerate the development of therapeutics against neurodegeneration. The current focus of OrganoTherapeutics is on Parkinson’s disease.See details»
OrganoTherapeutics - VentureRadar
LBV takes a unique model focused on lean operations, smart capital allocation, and diversified yet complementary nexus of 7 companies developing 10 first-in-class therapeutics. RDP Pharma …See details»
Technology - OrganoTherapeutics
Experimental analysis. Wet lab experiments based on the the project needs (neuronal phenotypes, autophagy, mitochondrial phenotypes, neuroinflammation, etc ).See details»
OrganoTherapeutics - Company info. interviews, news
OrganoTherapeutics is a spin-off project from the University of Luxembourg. OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective …See details»
OrganoTherapeutics SARL | Falling Walls
Founded in July 2019 by Prof. Dr. Jens Schwamborn and Dr. Javier Jarazo, the biotech company OrganoTherapeutics S.a.r.l. (OT) makes use of a proprietary human-specific 3D in vitro model, …See details»
OrganoTherapeutics | EU-Startups
OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinsons disease.See details»
Contacts, Employees, Board Members, Advisors & Alumni
OrganoTherapeutics use mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease.See details»
OrganoTherapeutics starts a collaboration with StressMarq …
Oct 26, 2023 The Luxembourg based biotech OrganoTherapeutics uses a patient-specific brain organoid model to research Parkinson’s Disease pathology in vitro and develop new …See details»
Biotech Spin-Off OrganoTherapeutics Gets Funding From KHAN-I
Aug 16, 2023 Having KHAN-I on board will certainly accelerate our efforts to further develop OrganoTherapeutics and develop novel therapeutics against Parkinson’s disease,” says Jens. …See details»
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins …
MIAMI, March 17, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief …See details»
OrganoTherapeutics and mo:re join forces on a pipeline for …
Jan 25, 2024 At OrganoTherapeutics, we produce midbrain organoids on a large scale for simultaneous testing of numerous therapeutics and conditions. With the capability to culture …See details»